phenoxybenzamine
Sign in to saveAlso known as Dibenzyline®, phenoxybenzamine hydrochloride, Fenoxibenzamina, Fenossibenzamina, POB, Phenoxybenzaminum
Phenoxybenzamine (PBZ), sold under the brand names Dibenzyline and Dibenyline, is a non-selective, irreversible alpha blocker.
Key facts
- Drug.verifiedrevid
- 464200638
- Drug.IUPAC_name
- (RS)-N-Benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine
- Drug.image
- Phenoxybenzamine2DCSD.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200px
- Drug.chirality
- Racemic mixture
- Drug.tradename
- Dibenzyline, Dibenyline
- Drug.MedlinePlus
- a682059
- Drug.pregnancy_AU
- B2
- Drug.pregnancy_US
- C
- Drug.routes_of_administration
- Oral
- Drug.elimination_half life
- 24 hours
- Drug.IUPHAR_ligand
- 7268
- Drug.CAS_number
- 59-96-1
- Drug.ATC_prefix
- C04
- Drug.ATC_suffix
- AX02
- Drug.PubChem
- 4768
- Drug.DrugBank
- DB00925
via Wikipedia infobox
Research
6,683 papers- Phenoxybenzamine hydrochloride.Report on carcinogens : carcinogen profiles · 2011
- Phenoxybenzamine in the treatment of hypoplastic left heart syndrome: a core review.Anesthesia and analgesia · 2007
- Phenoxybenzamine.The Journal of urology · 1977
- Phenoxybenzamine (hydrochloride).IARC monographs on the evaluation of the carcinogenic risk of chemicals to man · 1975
- Retrospective evaluation of the influence of phenoxybenzamine pretreatment on intraoperative cardiovascular variables in dogs with pheochromocytoma.The Canadian veterinary journal = La revue veterinaire canadienne · 2024
via PubMed
~5 min read
Encyclopedic overview
7 sectionsContents
- Uses
- Investigational
- Pharmacology
- Stereoisomerism
- See also
- References
- External links
Phenoxybenzamine (PBZ), sold under the brand names Dibenzyline and Dibenyline, is a non-selective, irreversible alpha blocker.
==Uses== It is used in the treatment of hypertension, and specifically that caused by pheochromocytoma. It has a slower onset and a longer-lasting effect compared with other alpha blockers.
Excerpted from Wikipedia’s “phenoxybenzamine” article, available under the CC BY-SA 4.0 licence.